Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
Giuseppe Curigliano, MD, PhD
Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Komal Jhaveri, MD, FACP
The Future of Oral SERDs: Combination Strategies
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
Routes Reconsidered: A Case-Based Debate in SERD Selection
Spotlight on Europe: Adapting the Evidence
Spotlight on Latin America: Closing the Gap
Cynthia Villarreal-Garza, MD, DSc
Spotlight on Asia-Pacific: Practice Beyond Borders
Hiraji Iwata, MD, PhD
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
Kathleen Moore, MD, MS
Joyce F. Liu, MD, MPH
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MOA: CDH6-Targeted Antibody-Drug Conjugates
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making
James M. Cleary, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.